{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:27:45Z","timestamp":1787110065097,"version":"build-2736575974"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105478","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:00:33Z","timestamp":1783782033000},"page":"105478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["TROP-2 in solid tumors: From oncogenic driver to therapeutic target with antibody-drug conjugates"],"prefix":"10.1016","volume":"225","author":[{"given":"Jinlin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinke","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105478_bib1","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.21037\/tlcr-2025-216","article-title":"Sacituzumab govitecan: a new hope for patients with pretreated extensive small-cell lung cancer (SCLC)-insights from the TROPiCS-03 trial","volume":"14","author":"Abbar","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113797","article-title":"Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy","volume":"155","author":"Ahmed","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105478_bib3","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.1007\/s00210-025-03901-w","article-title":"Marine peptides in lymphoma: surgery at molecular level for therapeutic understanding","volume":"398","author":"Ahmed","year":"2025","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.55730\/1300-0144.6061","article-title":"Unveiling the potential of marine peptides in leukemia: mechanistic insights and future horizon in peptide research","volume":"55","author":"Ahmed","year":"2025","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105478_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol. 43260-272. https\/\/"},{"key":"10.1016\/j.critrevonc.2026.105478_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17244021","article-title":"HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers","volume":"17","author":"Bagegni","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105478_bib7","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.2217\/fon-2021-0868","article-title":"A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer","volume":"17","author":"Bardia","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan \u00b1 durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib9","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic HR+\/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib10","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib13","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib14","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1038\/s41598-025-92697-z","article-title":"Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy","volume":"15","author":"Chang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105478_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18010151","article-title":"Targeting Cancer-Associated Fibroblasts in Prostate Cancer: Recent Advances and Therapeutic Opportunities","volume":"18","author":"Chen","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105478_bib16","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105478_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030394","article-title":"Acquired Resistance to Antibody-Drug Conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105478_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105478_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1186\/s12885-025-14402-7","article-title":"From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer- insights from the national cancer institute","volume":"25","author":"Ebrahim","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105478_bib20","article-title":"Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer","author":"Fleming","year":"2021","journal-title":"J. Adv. Pract. Oncol. 12747-752. https\/\/"},{"key":"10.1016\/j.critrevonc.2026.105478_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.12394","article-title":"TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis","volume":"10","author":"Foersch","year":"2024","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib22","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","article-title":"High expression of TROP2 correlates with poor prognosis in pancreatic cancer","volume":"99","author":"Fong","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105478_bib23","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","author":"Goldenberg","year":"2018","journal-title":"Oncotarget. 928989-29006. https\/\/"},{"key":"10.1016\/j.critrevonc.2026.105478_bib24","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105478_bib25","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib27","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105478_bib28","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.23.01207","article-title":"Targeting Trop-2 as a Cancer Driver","volume":"41","author":"Guerra","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib29","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1158\/1078-0432.CCR-15-1701","article-title":"Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors","volume":"22","author":"Guerra","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib30","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/1535-7163.MCT-22-0352","article-title":"3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability","volume":"22","author":"Guerra","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105478_bib31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.neo.2021.07.002","article-title":"Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer","volume":"23","author":"Guerra","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105478_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105478_bib33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.21037\/tcr-24-1870","article-title":"Deciding where Trop-2 directed antibody drug conjugates work in non-small cell lung cancer: the not so straightforward road","volume":"14","author":"Hsu","year":"2025","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib34","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1186\/s40001-025-03538-8","article-title":"The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis","volume":"30","author":"Huang","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib35","first-page":"1904","article-title":"Immuno-PET\/CT Imaging of Trop2 with [(18)F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation","volume":"65","author":"Huang","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib36","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s44321-024-00059-5","article-title":"ImmunoPET imaging of Trop2 in patients with solid tumours","volume":"16","author":"Huang","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib37","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105478_bib38","doi-asserted-by":"crossref","first-page":"22498","DOI":"10.1038\/s41598-022-27093-y","article-title":"Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer","volume":"12","author":"Izci","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105478_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70615","article-title":"Prognostic Value of Trop-2 Expression in Nonmetastatic Triple-Negative Breast Cancer and Correlation With Emerging Biomarkers","volume":"14","author":"Jacot","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib40","article-title":"Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs","volume":"17","author":"Jiang","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105478_bib41","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1186\/s12885-025-15042-7","article-title":"Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs","volume":"25","author":"Kanaan","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105478_bib42","doi-asserted-by":"crossref","first-page":"660","DOI":"10.21037\/tcr-24-1633","article-title":"The TROP2 paradox: enhancing precision in immunotherapy for advanced non-small cell lung cancer patients-a commentary","volume":"14","author":"Khan","year":"2025","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321555","article-title":"Trop-2 expression in non-small cell lung cancer","volume":"20","author":"Kuo","year":"2025","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105478_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113328","article-title":"Trop2: Jack of All Trades, Master of None","volume":"12","author":"Len\u00e1rt","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105478_bib45","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.2147\/DDDT.S489234","article-title":"Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer Treatment","volume":"18","author":"Li","year":"2024","journal-title":"Drug. Des. Devel Ther."},{"key":"10.1016\/j.critrevonc.2026.105478_bib46","article-title":"TROP2: as a promising target in lung cancer","volume":"15","author":"Li","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib47","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ddr.21870","article-title":"Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors","volume":"82","author":"Liao","year":"2021","journal-title":"Drug. Dev. Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051101","article-title":"The Expression of TP63 as a Biomarker of Early Recurrence in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy","volume":"12","author":"Lin","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105478_bib49","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/emmm.201200222","article-title":"TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma","volume":"4","author":"Lin","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib50","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105478_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1332489","article-title":"Targeting Trop2 in solid tumors: a look into structures and novel epitopes","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib52","article-title":"A TROP2-targeting ADC synergizes with oxidative phosphorylation inhibitor to enhance apoptosis in ESCC by suppressing the PI3K-AKT-mTOR signaling pathway","author":"Liu","year":"2025","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105478_bib53","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(23)01783-X","article-title":"Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some?","volume":"402","author":"Loibl","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105478_bib54","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","article-title":"Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors","volume":"25","author":"Lv","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib56","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.3390\/curroncol31090422","article-title":"Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer","volume":"31","author":"Manna","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib58","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/1078-0432.CCR-24-1948","article-title":"Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models","volume":"31","author":"Meric-Bernstam","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib60","doi-asserted-by":"crossref","first-page":"e1480","DOI":"10.1093\/oncolo\/oyae168","article-title":"Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors","volume":"29","author":"Morgenstern-Kaplan","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105478_bib61","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1074\/jbc.RA119.008084","article-title":"Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C \u03b1\/\u03b4 (PKC\u03b1\/\u03b4) enhances cell motility","volume":"294","author":"Mori","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105478_bib62","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41573-025-00121-y","article-title":"Dual-payload ADCs move into first oncology clinical trials","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105478_bib63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib64","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105478_bib65","article-title":"Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer","volume":"143","author":"Patel","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105478_bib66","article-title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol. 422860-2872. https\/\/"},{"key":"10.1016\/j.critrevonc.2026.105478_bib67","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study","author":"Pistilli","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib68","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188902","article-title":"Targeting Trop-2 in cancer: Recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105478_bib70","article-title":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","author":"Reck","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib71","doi-asserted-by":"crossref","first-page":"390","DOI":"10.21037\/atm-22-484","article-title":"Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer","volume":"10","author":"Rozenblit","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib72","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/fon-2020-0163","article-title":"TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+\/HER2- metastatic breast cancer","volume":"16","author":"Rugo","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235936","article-title":"Trop-2 as a Therapeutic Target in Breast Cancer","volume":"14","author":"Sakach","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105478_bib74","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib75","first-page":"73","article-title":"The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target","volume":"9","author":"Shen","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib76","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib77","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1101\/gad.196451.112","article-title":"Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via \u03b2-catenin signaling","volume":"26","author":"Stoyanova","year":"2012","journal-title":"Genes. Dev."},{"key":"10.1016\/j.critrevonc.2026.105478_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17111750","article-title":"Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data","volume":"17","author":"Stumpo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105478_bib79","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab Govitecan: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2026.105478_bib80","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib81","first-page":"165","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105478_bib82","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.3390\/curroncol29060312","article-title":"Trop-2 in Upper Tract Urothelial Carcinoma","volume":"29","author":"Tomiyama","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1495675","article-title":"Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions","volume":"15","author":"Tong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib84","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/jcp.24074","article-title":"Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the \u03b21 integrin-RACK1 axis","volume":"227","author":"Trerotola","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib85","doi-asserted-by":"crossref","first-page":"14318","DOI":"10.18632\/oncotarget.3960","article-title":"Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts","volume":"6","author":"Trerotola","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105478_bib86","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neo.2021.03.006","article-title":"Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis","volume":"23","author":"Trerotola","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105478_bib87","first-page":"14","article-title":"Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers","volume":"22","author":"Vranic","year":"2022","journal-title":"Bosn. J. Basic. Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105478_bib88","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","article-title":"FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer","volume":"27","author":"Wahby","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105478_bib89","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2498162","article-title":"Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations","volume":"17","author":"Wen","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.critrevonc.2026.105478_bib90","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.21037\/atm-22-5976","article-title":"A literature review of the promising future of TROP2: a potential drug therapy target","volume":"10","author":"Wen","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105478_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17080967","article-title":"A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs","volume":"17","author":"Wilski","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105478_bib92","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12105-021-01325-5","article-title":"Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target","volume":"15","author":"Wolber","year":"2021","journal-title":"Head. Neck Pathol."},{"key":"10.1016\/j.critrevonc.2026.105478_bib93","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12951-023-02183-9","article-title":"TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer","volume":"21","author":"Xu","year":"2023","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.critrevonc.2026.105478_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117863","article-title":"Evolution of TROP2: Biological insights and clinical applications","volume":"296","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105478_bib95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41523-023-00573-8","article-title":"Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan","volume":"9","author":"Zhao","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105478_bib96","doi-asserted-by":"crossref","DOI":"10.3892\/or.2025.8956","article-title":"Breaking therapeutic barriers in solid tumors: Clinical progress of antibody\u2011drug conjugate\/immune checkpoint inhibitor combinations (Review)","volume":"54","author":"Zheng","year":"2025","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105478_bib97","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.ccell.2025.09.012","article-title":"TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study","volume":"43","author":"Zhong","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105478_bib98","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12935-018-0589-9","article-title":"TROP2 methylation and expression in tamoxifen-resistant breast cancer","volume":"18","author":"Zimmers","year":"2018","journal-title":"Cancer Cell. Int."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:50:10Z","timestamp":1787107810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":98,"alternative-id":["S1040842826003653"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105478","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TROP-2 in solid tumors: From oncogenic driver to therapeutic target with antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105478"}}